Verve Therapeutics (VERV) PT Lowered to $30 at BMO Capital
Tweet Send to a Friend
BMO Capital analyst Kostas Biliouris lowered the price target on Verve Therapeutics (NASDAQ: VERV) to $30.00 (from $56.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
